サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1788388

バーチャル臨床試験の世界市場

Virtual Clinical Trials

出版日
ページ情報
英文 159 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.50円
バーチャル臨床試験の世界市場
出版日: 2025年08月12日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 159 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

バーチャル臨床試験の世界市場は2030年までに米国で141億米ドルに達する見込み

2024年に100億米ドルと推定されるバーチャル臨床試験の世界市場は、2024年から2030年にかけてCAGR 5.9%で成長し、2030年には141億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるインターベンショナルは、CAGR 5.5%を記録し、分析期間終了時には75億米ドルに達すると予測されます。観察セグメントの成長率は、分析期間中CAGR 6.8%と推定されます。

米国市場は26億米ドルと推定、中国はCAGR 5.7％で成長予測

米国のバーチャル臨床試験市場は、2024年に26億米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを5.7%として、2030年には市場規模が23億米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ5.2％と5.1％と予測されています。欧州では、ドイツがCAGR 4.7%で成長すると予測されています。

世界のバーチャル臨床試験市場- 主要動向と促進要因のまとめ

バーチャル臨床試験は医薬品開発の状況をどのように変えているか？

バーチャル臨床試験（VCTs）の出現は、製薬会社、バイオテクノロジー企業、研究開発機関が、参加者が物理的な治験施設を訪れることなく遠隔で臨床試験を実施できるようにし、従来の医薬品開発のアプローチに革命をもたらしました。VCTの採用は、より迅速で、費用対効果が高く、患者中心の調査手法の必要性から、近年著しく増加しています。地理的な制約やロジスティクスの課題、高い脱落率に阻まれがちな従来の臨床試験とは異なり、バーチャル臨床試験はデジタル技術を活用して、患者のリクルート、データ収集、リアルタイムのモニタリングを合理化します。モバイルヘルス（mヘルス）アプリ、ウェアラブルバイオセンサー、遠隔医療プラットフォーム、クラウドベースのデータ管理システムは、VCTに不可欠なものとなり、研究者は患者の健康状態を遠隔で追跡し、物理的な施設訪問なしに高品質の臨床データを収集できるようになりました。分散型臨床試験へのシフトはCOVID-19の大流行によって加速され、対面型臨床試験モデルの限界が浮き彫りになり、遠隔地臨床試験手法の可能性が浮き彫りになりました。規制当局がデジタル臨床試験の枠組みをますます支持し、製薬会社がバーチャル臨床試験プラットフォームに多額の投資を行っていることから、VCTは現代の臨床研究の標準となる準備が整っており、世界中の参加者にこれまでにない柔軟性とアクセシビリティを提供しています。

どのような技術革新がバーチャル臨床試験の採用を後押ししているのでしょうか？

バーチャル臨床試験の成功は、デジタルヘルス技術、人工知能（AI）、リアルタイムデータ解析の急速な進歩によるところが大きいです。VCTにおける最も革新的なイノベーションの1つは、AIを活用した患者募集ツールの統合です。このツールは、予測アルゴリズムを使用して、病歴、遺伝子データ、ライフスタイル要因に基づいて適切な候補者を特定します。このようなテクノロジーは、臨床研究における長年の課題に対処するため、患者募集のタイムラインを大幅に短縮し、患者の多様性を向上させる。ウェアラブル医療機器や遠隔モニタリングツールも、バイタルサイン、服薬アドヒアランス、疾患進行の継続的な追跡を実環境で可能にすることで、VCTに革命をもたらしています。ブロックチェーン技術は、仮想臨床試験におけるデータセキュリティと透明性をさらに強化し、規制基準への準拠を確保しながら、不変で改ざん不可能な臨床記録を提供します。さらに、クラウドベースの臨床試験管理システム（CTMS）の台頭により、データの保存、分析、利害関係者間のコラボレーションが合理化され、試験の効率性と拡張性が向上しています。また、遠隔医療とビデオ会議の統合により、臨床試験参加者と治験責任医師との直接的な交流が促進され、患者との高いエンゲージメントを維持しながら、物理的な訪問の必要性が減少しています。このような技術的進歩は、臨床試験の効率を向上させるだけでなく、データの正確性、規制遵守、臨床調査方法における患者の全体的な経験も向上させています。

バーチャル臨床試験の拡大を阻む課題とは？

バーチャル臨床試験は、その革新的な可能性にもかかわらず、普及の妨げとなるいくつかの課題に直面しています。最も差し迫った問題の一つは、規制の遵守です。国によって、デジタルヘルス技術や遠隔患者モニタリングに関するガイドラインや倫理的配慮が異なるからです。VCTは、患者の機密情報を保存するデジタル・プラットフォームに大きく依存しているため、サイバーセキュリティの脅威やデータ侵害に対して脆弱です。さらに、すべての患者が参加に必要な高速インターネット、スマートフォン、ウェアラブルデバイスを利用できるわけではないため、デジタルデバイドがバーチャルトライアルへのアクセシビリティに大きな障壁となっています。遠隔地からの参加は、患者と治験コーディネーター間の相互作用の減少につながり、データの質と継続率に影響を与える可能性があるため、治験期間を通じて患者のアドヒアランスとエンゲージメントを確保することも課題です。製薬企業と調査機関は、データの標準化、異なるデジタルヘルスプラットフォーム間の相互運用性、収集した臨床データの正確性と信頼性を確保するための遠隔モニタリングツールの検証に関する懸念にも対処しなければならないです。これらの課題を克服するには、規制当局、テクノロジープロバイダー、ヘルスケア機関が協力して、バーチャル臨床試験を効果的に実施するための標準化されたフレームワークとベストプラクティスを確立する必要があります。

バーチャル臨床試験市場の成長を促進する要因とは？

バーチャル臨床試験市場の成長は、デジタルヘルス技術の採用の増加、分散型臨床研究に対する需要の高まり、費用対効果が高く時間効率の高い調査手法の必要性など、いくつかの要因によって牽引されています。慢性疾患や希少疾患の有病率の増加により、多様な患者代表を確保しながら医薬品開発を加速できる革新的な試験アプローチが必要とされています。AIを活用した患者募集やリアルタイム・モニタリング・ソリューションの拡大も市場成長に寄与しており、研究者は効率性を高めた大規模試験を実施できるようになりました。米国食品医薬品局（FDA）や欧州医薬品庁（EMA）などの規制機関が分散型試験を支持するようになっていることも、企業が進化するコンプライアンス要件に対応しようとしていることから、業界の採用をさらに後押ししています。また、製薬企業や医薬品開発業務受託機関（CRO）による仮想臨床試験インフラへの投資が急増しており、業界各社はAIを活用したデータ分析、ブロックチェーンを活用したセキュリティソリューション、クラウドベースの臨床試験プラットフォームに注力しており、市場拡大の原動力となっています。患者中心の臨床試験デザインを重視する傾向が強まっていることに加え、ウェアラブル健康モニタリングデバイスの採用が増加していることから、バーチャル臨床試験市場はさらに推進され、医薬品開発と臨床研究の将来における重要な柱として位置づけられると予想されます。

セグメント

試験デザイン（介入、観察、拡大アクセス）、適応症（中枢神経系、自己免疫／炎症、心血管疾患、代謝／内分泌、感染症、腫瘍、泌尿生殖器、眼科、その他）

調査対象企業の例

  • Castor
  • Clinical Ink Inc.
  • Covance Inc.（LabCorp）
  • CRF Health
  • ICON plc
  • IQVIA
  • LEO Innovation Lab
  • Medable Inc.
  • Medidata Solutions（Dassault Systemes SE）
  • Medpace Holdings Inc.
  • Novotech
  • Oracle Corporation
  • Parexel International Corporation
  • PRA Health Sciences
  • Science 37
  • Signant Health
  • Syneos Health
  • THREAD Research
  • Velocity Clinical Research
  • Wuxi AppTec

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中のドメイン専門家からキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP33288

Global Virtual Clinical Trials Market to Reach US$14.1 Billion by 2030

The global market for Virtual Clinical Trials estimated at US$10.0 Billion in the year 2024, is expected to reach US$14.1 Billion by 2030, growing at a CAGR of 5.9% over the analysis period 2024-2030. Interventional, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$7.5 Billion by the end of the analysis period. Growth in the Observational segment is estimated at 6.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.6 Billion While China is Forecast to Grow at 5.7% CAGR

The Virtual Clinical Trials market in the U.S. is estimated at US$2.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.3 Billion by the year 2030 trailing a CAGR of 5.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.2% and 5.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR.

Global Virtual Clinical Trials Market - Key Trends & Drivers Summarized

How Are Virtual Clinical Trials Transforming the Drug Development Landscape?

The emergence of virtual clinical trials (VCTs) has revolutionized the traditional approach to drug development, enabling pharmaceutical companies, biotech firms, and research organizations to conduct clinical trials remotely without requiring participants to visit physical trial sites. The adoption of VCTs has significantly increased in recent years, driven by the need for faster, cost-effective, and more patient-centric trial methodologies. Unlike conventional trials, which are often hindered by geographical constraints, logistical challenges, and high dropout rates, virtual trials leverage digital technologies to streamline patient recruitment, data collection, and real-time monitoring. Mobile health (mHealth) apps, wearable biosensors, telemedicine platforms, and cloud-based data management systems have become integral to VCTs, allowing researchers to track patient health remotely and collect high-quality clinical data without physical site visits. The shift toward decentralized clinical trials has been accelerated by the COVID-19 pandemic, which underscored the limitations of in-person trial models and highlighted the potential of remote trial methodologies. With regulatory agencies increasingly endorsing digital trial frameworks and pharmaceutical companies investing heavily in virtual trial platforms, VCTs are poised to become the standard for modern clinical research, offering unprecedented flexibility and accessibility for participants worldwide.

What Technological Innovations Are Driving the Adoption of Virtual Clinical Trials?

The success of virtual clinical trials is largely attributed to rapid advancements in digital health technologies, artificial intelligence (AI), and real-time data analytics. One of the most transformative innovations in VCTs is the integration of AI-driven patient recruitment tools, which use predictive algorithms to identify suitable candidates based on medical history, genetic data, and lifestyle factors. These technologies significantly reduce recruitment timelines and enhance patient diversity, addressing long-standing challenges in clinical research. Wearable medical devices and remote monitoring tools have also revolutionized VCTs by enabling continuous tracking of vital signs, medication adherence, and disease progression in real-world settings. Blockchain technology is further enhancing data security and transparency in virtual trials, providing immutable and tamper-proof clinical records while ensuring compliance with regulatory standards. Additionally, the rise of cloud-based clinical trial management systems (CTMS) has streamlined data storage, analysis, and collaboration between stakeholders, improving trial efficiency and scalability. The integration of telemedicine and video conferencing has also facilitated direct interactions between trial participants and investigators, reducing the need for physical visits while maintaining high levels of patient engagement. These technological advancements are not only improving trial efficiency but also enhancing data accuracy, regulatory compliance, and overall patient experience in the clinical research process.

What Challenges Are Hindering the Expansion of Virtual Clinical Trials?

Despite their transformative potential, virtual clinical trials face several challenges that could hinder their widespread adoption. One of the most pressing issues is regulatory compliance, as different countries have varying guidelines and ethical considerations regarding digital health technologies and remote patient monitoring. Ensuring data privacy and security is another major concern, as VCTs rely heavily on digital platforms that store sensitive patient information, making them vulnerable to cybersecurity threats and data breaches. Additionally, the digital divide poses a significant barrier to virtual trial accessibility, as not all patients have access to high-speed internet, smartphones, or wearable devices required for participation. Another challenge lies in ensuring patient adherence and engagement throughout the trial period, as remote participation may lead to reduced interaction between patients and trial coordinators, impacting data quality and retention rates. Pharmaceutical companies and research organizations must also address concerns related to data standardization, interoperability between different digital health platforms, and the validation of remote monitoring tools to ensure the accuracy and reliability of collected clinical data. Overcoming these challenges will require a collaborative effort between regulatory agencies, technology providers, and healthcare institutions to establish standardized frameworks and best practices for conducting virtual clinical trials effectively.

What Factors Are Driving the Growth of the Virtual Clinical Trials Market?

The growth in the virtual clinical trials market is driven by several factors, including the increasing adoption of digital health technologies, rising demand for decentralized clinical research, and the need for cost-effective and time-efficient trial methodologies. The growing prevalence of chronic diseases and rare conditions has necessitated innovative trial approaches that can accelerate drug development while ensuring diverse patient representation. The expansion of AI-driven patient recruitment and real-time monitoring solutions has also contributed to market growth, enabling researchers to conduct large-scale trials with enhanced efficiency. The increasing support from regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for decentralized trials has further bolstered industry adoption, as companies seek to align with evolving compliance requirements. Additionally, the surge in investments from pharmaceutical companies and contract research organizations (CROs) in virtual trial infrastructure is driving market expansion, with industry players focusing on AI-powered data analytics, blockchain-based security solutions, and cloud-based clinical trial platforms. The growing emphasis on patient-centric trial designs, along with the rising adoption of wearable health monitoring devices, is expected to further propel the virtual clinical trials market, positioning it as a key pillar in the future of drug development and clinical research.

SCOPE OF STUDY:

The report analyzes the Virtual Clinical Trials market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Study Design (Interventional, Observational, Expanded Access); Indication (CNS, Autoimmune / Inflammation, Cardiovascular Disease, Metabolic / Endocrinology, Infectious Disease, Oncology, Genitourinary, Ophthalmology, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 47 Featured) -

  • Castor
  • Clinical Ink Inc.
  • Covance Inc. (LabCorp)
  • CRF Health
  • ICON plc
  • IQVIA
  • LEO Innovation Lab
  • Medable Inc.
  • Medidata Solutions (Dassault Systemes SE)
  • Medpace Holdings Inc.
  • Novotech
  • Oracle Corporation
  • Parexel International Corporation
  • PRA Health Sciences
  • Science 37
  • Signant Health
  • Syneos Health
  • THREAD Research
  • Velocity Clinical Research
  • Wuxi AppTec

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Virtual Clinical Trials - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Demand for Decentralized Research Models Spurs Adoption of Virtual Clinical Trials
    • Pandemic-Driven Disruption in Traditional Trial Operations Strengthens Business Case for Remote Models
    • Widespread Availability of Digital Health Technologies Expands Addressable Market Opportunity
    • Regulatory Support for Remote Monitoring and eConsent Platforms Drives Adoption Momentum
    • Integration of Wearables and Mobile Sensors Generates Real-Time Patient Data for Trials
    • Telemedicine Platforms and Video Consultations Propel Growth in Patient-Centric Trial Designs
    • Rising Emphasis on Diversity and Geographic Inclusion Throws the Spotlight on Virtual Participation Models
    • Cost Reduction Pressures in Pharma R&D Strengthen Case for Digitized Trial Methodologies
    • Globalization of Clinical Research Drives Need for Scalable, Virtual Protocols
    • Data-Driven Trial Management Platforms Generate Demand for Advanced Analytics Integration
    • AI and Machine Learning Enable Intelligent Site Selection and Predictive Trial Forecasting
    • Blockchain Integration Enhances Data Integrity, Transparency, and Patient Trust
    • Cloud-Based Electronic Data Capture (EDC) Systems Spur Growth in Decentralized Trial Execution
    • High Dropout Rates in Traditional Trials Drive Demand for Patient-Friendly Virtual Engagement Tools
    • Wearable Biosensors and Remote Patient Monitoring Accelerate Adoption in Chronic Disease Studies
    • Expansion of Precision Medicine and Personalized Therapies Supports Real-Time Virtual Models
    • Hybrid Trial Designs Combining Virtual and Physical Elements Sustain Market Growth
    • Regulatory Flexibility and Guidance Updates Propel Industry-Wide Standardization of Virtual Trials
    • Interoperability Across EHR Systems and ePRO Tools Generates Opportunities for Seamless Data Flow
    • Integration of Real-World Data (RWD) and Real-World Evidence (RWE) Strengthens Outcome Assessments
    • Patient Empowerment and Remote Accessibility Generate Accelerated Demand for Virtual Platforms
    • Growth in Rare Disease and Orphan Drug Studies Highlights Advantages of Remote Trial Recruitment
    • Expansion of 5G Infrastructure and IoT Connectivity Enhances Digital Trial Feasibility
    • Strategic Collaborations Between Tech Providers and CROs Bolster Global Trial Scalability
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Virtual Clinical Trials Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Virtual Clinical Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Virtual Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Interventional by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Interventional by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Observational by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Observational by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Expanded Access by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Expanded Access by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Genitourinary by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Genitourinary by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Ophthalmology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Ophthalmology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for CNS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for CNS by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Autoimmune / Inflammation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Autoimmune / Inflammation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Cardiovascular Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Metabolic / Endocrinology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Metabolic / Endocrinology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Infectious Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Infectious Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Virtual Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 28: USA Recent Past, Current & Future Analysis for Virtual Clinical Trials by Study Design - Interventional, Observational and Expanded Access - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for Virtual Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Expanded Access for the Years 2025 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for Virtual Clinical Trials by Indication - Genitourinary, Ophthalmology, Others, CNS, Autoimmune / Inflammation, Cardiovascular Disease, Metabolic / Endocrinology, Infectious Disease and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for Virtual Clinical Trials by Indication - Percentage Breakdown of Value Sales for Genitourinary, Ophthalmology, Others, CNS, Autoimmune / Inflammation, Cardiovascular Disease, Metabolic / Endocrinology, Infectious Disease and Oncology for the Years 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Virtual Clinical Trials by Study Design - Interventional, Observational and Expanded Access - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for Virtual Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Expanded Access for the Years 2025 & 2030
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Virtual Clinical Trials by Indication - Genitourinary, Ophthalmology, Others, CNS, Autoimmune / Inflammation, Cardiovascular Disease, Metabolic / Endocrinology, Infectious Disease and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for Virtual Clinical Trials by Indication - Percentage Breakdown of Value Sales for Genitourinary, Ophthalmology, Others, CNS, Autoimmune / Inflammation, Cardiovascular Disease, Metabolic / Endocrinology, Infectious Disease and Oncology for the Years 2025 & 2030
  • JAPAN
    • Virtual Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 36: Japan Recent Past, Current & Future Analysis for Virtual Clinical Trials by Study Design - Interventional, Observational and Expanded Access - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Japan 6-Year Perspective for Virtual Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Expanded Access for the Years 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Virtual Clinical Trials by Indication - Genitourinary, Ophthalmology, Others, CNS, Autoimmune / Inflammation, Cardiovascular Disease, Metabolic / Endocrinology, Infectious Disease and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for Virtual Clinical Trials by Indication - Percentage Breakdown of Value Sales for Genitourinary, Ophthalmology, Others, CNS, Autoimmune / Inflammation, Cardiovascular Disease, Metabolic / Endocrinology, Infectious Disease and Oncology for the Years 2025 & 2030
  • CHINA
    • Virtual Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 40: China Recent Past, Current & Future Analysis for Virtual Clinical Trials by Study Design - Interventional, Observational and Expanded Access - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: China 6-Year Perspective for Virtual Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Expanded Access for the Years 2025 & 2030
    • TABLE 42: China Recent Past, Current & Future Analysis for Virtual Clinical Trials by Indication - Genitourinary, Ophthalmology, Others, CNS, Autoimmune / Inflammation, Cardiovascular Disease, Metabolic / Endocrinology, Infectious Disease and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: China 6-Year Perspective for Virtual Clinical Trials by Indication - Percentage Breakdown of Value Sales for Genitourinary, Ophthalmology, Others, CNS, Autoimmune / Inflammation, Cardiovascular Disease, Metabolic / Endocrinology, Infectious Disease and Oncology for the Years 2025 & 2030
  • EUROPE
    • Virtual Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Virtual Clinical Trials by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe 6-Year Perspective for Virtual Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 46: Europe Recent Past, Current & Future Analysis for Virtual Clinical Trials by Study Design - Interventional, Observational and Expanded Access - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Europe 6-Year Perspective for Virtual Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Expanded Access for the Years 2025 & 2030
    • TABLE 48: Europe Recent Past, Current & Future Analysis for Virtual Clinical Trials by Indication - Genitourinary, Ophthalmology, Others, CNS, Autoimmune / Inflammation, Cardiovascular Disease, Metabolic / Endocrinology, Infectious Disease and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for Virtual Clinical Trials by Indication - Percentage Breakdown of Value Sales for Genitourinary, Ophthalmology, Others, CNS, Autoimmune / Inflammation, Cardiovascular Disease, Metabolic / Endocrinology, Infectious Disease and Oncology for the Years 2025 & 2030
  • FRANCE
    • Virtual Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for Virtual Clinical Trials by Study Design - Interventional, Observational and Expanded Access - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: France 6-Year Perspective for Virtual Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Expanded Access for the Years 2025 & 2030
    • TABLE 52: France Recent Past, Current & Future Analysis for Virtual Clinical Trials by Indication - Genitourinary, Ophthalmology, Others, CNS, Autoimmune / Inflammation, Cardiovascular Disease, Metabolic / Endocrinology, Infectious Disease and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: France 6-Year Perspective for Virtual Clinical Trials by Indication - Percentage Breakdown of Value Sales for Genitourinary, Ophthalmology, Others, CNS, Autoimmune / Inflammation, Cardiovascular Disease, Metabolic / Endocrinology, Infectious Disease and Oncology for the Years 2025 & 2030
  • GERMANY
    • Virtual Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 54: Germany Recent Past, Current & Future Analysis for Virtual Clinical Trials by Study Design - Interventional, Observational and Expanded Access - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Germany 6-Year Perspective for Virtual Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Expanded Access for the Years 2025 & 2030
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Virtual Clinical Trials by Indication - Genitourinary, Ophthalmology, Others, CNS, Autoimmune / Inflammation, Cardiovascular Disease, Metabolic / Endocrinology, Infectious Disease and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Germany 6-Year Perspective for Virtual Clinical Trials by Indication - Percentage Breakdown of Value Sales for Genitourinary, Ophthalmology, Others, CNS, Autoimmune / Inflammation, Cardiovascular Disease, Metabolic / Endocrinology, Infectious Disease and Oncology for the Years 2025 & 2030
  • ITALY
    • TABLE 58: Italy Recent Past, Current & Future Analysis for Virtual Clinical Trials by Study Design - Interventional, Observational and Expanded Access - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Italy 6-Year Perspective for Virtual Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Expanded Access for the Years 2025 & 2030
    • TABLE 60: Italy Recent Past, Current & Future Analysis for Virtual Clinical Trials by Indication - Genitourinary, Ophthalmology, Others, CNS, Autoimmune / Inflammation, Cardiovascular Disease, Metabolic / Endocrinology, Infectious Disease and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Italy 6-Year Perspective for Virtual Clinical Trials by Indication - Percentage Breakdown of Value Sales for Genitourinary, Ophthalmology, Others, CNS, Autoimmune / Inflammation, Cardiovascular Disease, Metabolic / Endocrinology, Infectious Disease and Oncology for the Years 2025 & 2030
  • UNITED KINGDOM
    • Virtual Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 62: UK Recent Past, Current & Future Analysis for Virtual Clinical Trials by Study Design - Interventional, Observational and Expanded Access - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: UK 6-Year Perspective for Virtual Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Expanded Access for the Years 2025 & 2030
    • TABLE 64: UK Recent Past, Current & Future Analysis for Virtual Clinical Trials by Indication - Genitourinary, Ophthalmology, Others, CNS, Autoimmune / Inflammation, Cardiovascular Disease, Metabolic / Endocrinology, Infectious Disease and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: UK 6-Year Perspective for Virtual Clinical Trials by Indication - Percentage Breakdown of Value Sales for Genitourinary, Ophthalmology, Others, CNS, Autoimmune / Inflammation, Cardiovascular Disease, Metabolic / Endocrinology, Infectious Disease and Oncology for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 66: Rest of Europe Recent Past, Current & Future Analysis for Virtual Clinical Trials by Study Design - Interventional, Observational and Expanded Access - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Rest of Europe 6-Year Perspective for Virtual Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Expanded Access for the Years 2025 & 2030
    • TABLE 68: Rest of Europe Recent Past, Current & Future Analysis for Virtual Clinical Trials by Indication - Genitourinary, Ophthalmology, Others, CNS, Autoimmune / Inflammation, Cardiovascular Disease, Metabolic / Endocrinology, Infectious Disease and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Rest of Europe 6-Year Perspective for Virtual Clinical Trials by Indication - Percentage Breakdown of Value Sales for Genitourinary, Ophthalmology, Others, CNS, Autoimmune / Inflammation, Cardiovascular Disease, Metabolic / Endocrinology, Infectious Disease and Oncology for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Virtual Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 70: Asia-Pacific Recent Past, Current & Future Analysis for Virtual Clinical Trials by Study Design - Interventional, Observational and Expanded Access - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Asia-Pacific 6-Year Perspective for Virtual Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Expanded Access for the Years 2025 & 2030
    • TABLE 72: Asia-Pacific Recent Past, Current & Future Analysis for Virtual Clinical Trials by Indication - Genitourinary, Ophthalmology, Others, CNS, Autoimmune / Inflammation, Cardiovascular Disease, Metabolic / Endocrinology, Infectious Disease and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Asia-Pacific 6-Year Perspective for Virtual Clinical Trials by Indication - Percentage Breakdown of Value Sales for Genitourinary, Ophthalmology, Others, CNS, Autoimmune / Inflammation, Cardiovascular Disease, Metabolic / Endocrinology, Infectious Disease and Oncology for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 74: Rest of World Recent Past, Current & Future Analysis for Virtual Clinical Trials by Study Design - Interventional, Observational and Expanded Access - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Rest of World 6-Year Perspective for Virtual Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Expanded Access for the Years 2025 & 2030
    • TABLE 76: Rest of World Recent Past, Current & Future Analysis for Virtual Clinical Trials by Indication - Genitourinary, Ophthalmology, Others, CNS, Autoimmune / Inflammation, Cardiovascular Disease, Metabolic / Endocrinology, Infectious Disease and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Rest of World 6-Year Perspective for Virtual Clinical Trials by Indication - Percentage Breakdown of Value Sales for Genitourinary, Ophthalmology, Others, CNS, Autoimmune / Inflammation, Cardiovascular Disease, Metabolic / Endocrinology, Infectious Disease and Oncology for the Years 2025 & 2030

IV. COMPETITION